Galectin Therapeutics (GALT) CFO granted new stock options and RSUs

Rhea-AI Filing Summary

Galectin Therapeutics Inc. Chief Financial Officer Jack W. Callicutt reported new equity awards from the company. On January 16, 2026, he received a stock option for 65,000 shares of common stock at an exercise price of $3.04 per share, expiring on January 16, 2036. The options vest in four equal 25% installments on June 30, 2026, December 31, 2026, June 30, 2027, and December 31, 2027.

On the same date, he was also granted 100,000 Restricted Stock Units. These RSUs vest 100% on the earlier of December 31, 2026 or the signing of a partnership agreement, and, if vested, convert into common stock on a one-for-one basis. All awards were issued under the Galectin Therapeutics, Inc. 2019 Omnibus Equity Incentive Plan, and are reported as directly owned by the officer.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

CALLICUTT JACK W

(Last) (First) (Middle)

C/O GALECTIN THERAPEUTICS INC.

4960 PEACHTREE INDUSTRIAL BLVD., STE 240

(Street)

NORCROSS GA 30071

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
GALECTIN THERAPEUTICS INC [ GALT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Financial Officer

3. Date of Earliest Transaction (Month/Day/Year)
01/16/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock option (right to buy)(1)	$3.04	01/16/2026		A		65,000		(2)	01/16/2036	Common Stock	65,000	$0	65,000	D
Restricted Stock Unit(1)	(4)	01/16/2026		A		100,000		(3)	(3)	Common Stock	100,000	$0	100,000	D

Explanation of Responses:

1. Issued pursuant to the Galectin Therapeutics, Inc. 2019 Omnibus Equity Incentive Plan.

2. The options vest as follows: 25% on each of June 30, 2026? December 31, 2026? June 30, 2027? and December 31, 2027.

3. Restricted Stock Units vest 100% on the earlier of December 31, 2026 or signing of a partnership agreement.

4. The Restricted Stock Units, if vested, convert into Common Stock on a one for one basis.

	Jack W. Callicutt	01/21/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What equity awards did GALT grant to its CFO Jack W. Callicutt?

Galectin Therapeutics Inc. granted its Chief Financial Officer 65,000 stock options with a $3.04 exercise price and 100,000 Restricted Stock Units, both dated January 16, 2026.

How do Jack W. Callicutt’s new stock options at GALT vest?

The 65,000 stock options vest in four equal 25% installments on June 30, 2026, December 31, 2026, June 30, 2027, and December 31, 2027, and expire on January 16, 2036.

What are the vesting conditions for the 100,000 RSUs reported by GALT’s CFO?

The 100,000 Restricted Stock Units vest 100% on the earlier of December 31, 2026 or the signing of a partnership agreement, and then convert into common stock on a one-for-one basis.

Are the new GALT equity awards to the CFO direct or indirect holdings?

Both the 65,000 stock options and the 100,000 RSUs are reported as directly owned by Jack W. Callicutt, with no indirect ownership entity noted.

Under which plan were the CFO’s GALT options and RSUs issued?

The stock options and RSUs granted to the CFO were issued under the Galectin Therapeutics, Inc. 2019 Omnibus Equity Incentive Plan, as described in the filing footnotes.

How many derivative securities does GALT’s CFO hold after these grants?

Following the reported transactions, Jack W. Callicutt holds 65,000 stock options and 100,000 Restricted Stock Units as derivative securities related to Galectin Therapeutics Inc. common stock.